Immunomodulatory Effects of Newcastle Disease Virus AF2240 Strain on Human Peripheral Blood Mononuclear Cells

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2014 Oct 16

PMID 25317070

Citations 8

Authors

Han Yuen Lam

Khatijah Yusoff

Swee Keong Yeap

Tamilselvan Subramani

Suraini Abd-Aziz

Abdul Rahman Omar

Noorjahan Banu Alitheen

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has raised the attention of many scientists because it hold promise to be an attractive therapeutic strategy to treat a number of disorders. In this study, the immunomodulatory effects of low titers of Newcastle disease virus (NDV) AF2240 on human peripheral blood mononuclear cells (PBMC) were analyzed. We evaluated cytokine secretion and PBMC activation by cell proliferation assay, immunophenotyping and enzyme linked immunosorbent assay. The proliferation of the human PBMC was measured to be 28.5% and 36.5% upon treatment with 8 hemaglutinin unit (HAU) and 2 HAU of NDV respectively. Interestingly, the percentage of cells with activating markers CD16 and CD56 were increased significantly. Furthermore, the intracellular perforin and granzyme levels were also increased upon virus infection. Human PBMC treated with NDV titer 8 HAU was found to stimulate the highest level of cytokine production including interferon-γ, interleukin-2 and interleukin-12. The release of these proteins contributes to the antitumor effect of PBMC against MCF-7 breast cancer cells. Based on the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, activated human PBMC showed high cytolytic efficiency towards human breast tumor cells. In summary, NDV was able to stimulate PBMC proliferation, cytokine secretion and cytolytic activity.

Citing Articles

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus.

Pathak U, Pal R, Malik N Life (Basel). 2023; 13(8).

PMID: 37629483 PMC: 10455894. DOI: 10.3390/life13081626.

Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model.

Ortega-Rivera O, Gallegos-Alcala P, Jimenez M, Quintanar J, Torres-Juarez F, Rivas-Santiago B J Breast Cancer. 2023; 26(2):186-200.

PMID: 37051644 PMC: 10139849. DOI: 10.4048/jbc.2023.26.e9.

Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.

Vannini A, Leoni V, Campadelli-Fiume G Adv Exp Med Biol. 2021; 1290:67-80.

PMID: 33559855 DOI: 10.1007/978-3-030-55617-4_4.

Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo.

Syed Najmuddin S, Amin Z, Tan S, Yeap S, Kalyanasundram J, Ani M Cancer Cell Int. 2020; 20:278.

PMID: 32612457 PMC: 7325054. DOI: 10.1186/s12935-020-01372-y.

Evaluation of a Recombinant Newcastle Disease Virus Expressing Human IL12 against Human Breast Cancer.

Amin Z, Ani M, Tan S, Yeap S, Alitheen N, Syed Najmuddin S Sci Rep. 2019; 9(1):13999.

PMID: 31570732 PMC: 6768883. DOI: 10.1038/s41598-019-50222-z.

References

Carlens S, Gilljam M, Chambers B, Aschan J, Guven H, Ljunggren H . A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001; 62(10):1092-8. DOI: 10.1016/s0198-8859(01)00313-5. View

Hanna W, Wolbink A, Wever P, Kummer J, Kummer A, Swaak A . Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol. 1998; 160(7):3610-6. View

Yeap S, Alitheen N, Ali A, Omar A, Raha A, Suraini A . Effect of Rhaphidophora korthalsii methanol extract on human peripheral blood mononuclear cell (PBMC) proliferation and cytolytic activity toward HepG2. J Ethnopharmacol. 2007; 114(3):406-11. DOI: 10.1016/j.jep.2007.08.020. View

Ortaldo J, Winkler-Pickett R, Wigginton J, Horner M, Bere E, Mason A . Regulation of ITAM-positive receptors: role of IL-12 and IL-18. Blood. 2005; 107(4):1468-75. PMC: 1895416. DOI: 10.1182/blood-2005-04-1579. View

Radaev S, Motyka S, Fridman W, Sautes-Fridman C, Sun P . The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem. 2001; 276(19):16469-77. DOI: 10.1074/jbc.M100350200. View

Jarahian M, Watzl C, Fournier P, Arnold A, Djandji D, Zahedi S . Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol. 2009; 83(16):8108-21. PMC: 2715740. DOI: 10.1128/JVI.00211-09. View

Biron C, Nguyen K, Pien G, Cousens L, Salazar-Mather T . Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17:189-220. DOI: 10.1146/annurev.immunol.17.1.189. View

Brazowski E, Eytan K, Eisenthal A . In vitro modulation of interleukin-2-mediated human peripheral mononuclear cell proliferation and antitumor cytotoxicity by 5-fluorouracil. Anticancer Res. 2008; 27(6B):4135-41. View

Molouki A, Hsu Y, Jahanshiri F, Rosli R, Yusoff K . Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in HeLa cells. Intervirology. 2009; 53(2):87-94. DOI: 10.1159/000264198. View

10.

Schirrmacher V . Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother. 2005; 54(6):587-98. PMC: 11042470. DOI: 10.1007/s00262-004-0602-0. View

11.

Chulan U, Ibrahim A, Babjee A, Sheikh-Omar A . Vaccination against Newcastle disease. Trop Anim Health Prod. 1982; 14(3):177-84. DOI: 10.1007/BF02242152. View

12.

Zeng J, Fournier P, Schirrmacher V . Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 2002; 297(1):19-30. DOI: 10.1006/viro.2002.1413. View

13.

Reichard K, Lorence R, Cascino C, Peeples M, Walter R, Fernando M . Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992; 52(5):448-53. DOI: 10.1016/0022-4804(92)90310-v. View

14.

Iversen A, Norris P, Ware C, Benedict C . Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol. 2005; 175(11):7568-74. DOI: 10.4049/jimmunol.175.11.7568. View

15.

Kobayashi S, Sato R, Aoki T, Omoe K, Inanami O, Hankanga C . Effect of bovine lactoferrin on functions of activated feline peripheral blood mononuclear cells during chronic feline immunodeficiency virus infection. J Vet Med Sci. 2008; 70(5):429-35. DOI: 10.1292/jvms.70.429. View

16.

Sturlan S, Sachet M, Baumann S, Kuznetsova I, Spittler A, Bergmann M . Influenza a virus induces an immediate cytotoxic activity in all major subsets of peripheral blood mononuclear cells. PLoS One. 2009; 4(1):e4122. PMC: 2610492. DOI: 10.1371/journal.pone.0004122. View

17.

Umansky V, Shatrov V, Lehmann V, Schirrmacher V . Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol. 1996; 8(4):491-8. DOI: 10.1093/intimm/8.4.491. View

18.

Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C . Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999; 6(1):63-73. DOI: 10.1038/sj.gt.3300787. View

19.

Lorence R, Rood P, Kelley K . Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst. 1988; 80(16):1305-12. DOI: 10.1093/jnci/80.16.1305. View

20.

Krishnamurthy S, Takimoto T, Scroggs R, Portner A . Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol. 2006; 80(11):5145-55. PMC: 1472132. DOI: 10.1128/JVI.02618-05. View